Physician profile
Barry S Ross
NPI 1508809039
$10,290.95
in general payments reported to CMS, 2019-2025
38 companies · $1,498 in 2025
The $1,498 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $618 · 2021: $1,257 · 2022: $2,075 · 2023: $2,170 · 2024: $1,599 · 2025: $1,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,266.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,001.78 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,100.60 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $808.45 | 2020-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $584.24 | 2019-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $484.52 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $399.00 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $297.84 | 2023-2025 | |
| Pfizer INC. | $230.97 | 2019-2025 | |
| Lilly USA, LLC | $210.58 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $196.43 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $168.31 | 2019-2025 | |
| Redhill Biopharma INC. | $159.34 | 2020-2023 | Talicia |
| Cumberland Pharmaceuticals, INC. | $157.31 | 2021-2022 | |
| Daiichi Sankyo INC. | $124.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $123.98 | 2023 | Zeposia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $123.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $121.38 | 2024-2025 | Tremfya |
| Braintree Laboratories, INC. | $116.23 | 2020-2024 | Sutab, Suflave |
| Shire North American Group INC | $102.12 | 2019 | |
| Evoke Pharma, INC. | $95.89 | 2021-2024 | Gimoti |
| Ironwood Pharmaceuticals, INC | $89.88 | 2022-2025 | Linzess |
| Aimmune Therapeutics, INC. | $86.34 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $75.59 | 2019-2025 | Clenpiq |
| Pharmacosmos Therapeutics INC. | $66.21 | 2022-2023 | Monoferric |
| Concordia Pharmaceuticals INC. | $47.02 | 2019 | |
| Allergan, INC. | $46.61 | 2019 | |
| Vivus LLC | $37.18 | 2022-2024 | Pancreaze |
| Capsovision, INC. | $36.67 | 2023 | Capsocam Plus |
| Organon LLC | $25.53 | 2021-2023 | Renflexis |
| Cook Medical LLC | $25.51 | 2020 | |
| Mylan Institutional INC. | $22.45 | 2023 | Hulio |
| Regeneron Healthcare Solutions, INC. | $20.78 | 2025 | Dupixent |
| Fresenius Kabi USA, LLC | $18.50 | 2023 | Idacio |
| Phathom Pharmaceuticals, INC. | $18.43 | 2024 | Voquezna |
| Alfasigma USA, INC. | $17.92 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.81 | 2021 | |
| Ucb, INC. | $16.45 | 2021 | |
| Amgen INC. | $16.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.